COMMUNIQUÉS West-GlobeNewswire

Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade
20/05/2026
Plans to File CTA for Ph. 1b, FIH Study, 30 – 40 Advanced Cancer Patients in ‘26 MELBOURNE, Australia, May 20, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a [...]
Regional Health Properties Reports First Quarter 2026 Results
20/05/2026
Reported First Quarter Revenue of $21.2 million Generated Adjusted EBITDA from Operations of $0.5 million Continued Execution of Integrated Healthcare Platform Strategy ATLANTA, GA, May 20, 2026 (GLOBE NEWSWIRE) -- [...]
C4 Therapeutics to Participate in Upcoming Conferences
20/05/2026
WATERTOWN, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today [...]
Lung Health Foundation Says Canada’s Current Access System to Emerging Therapies is Moving Slower than Modern Medicine
20/05/2026
New lung cancer and respiratory treatments are being developed faster than critically ill Canadian patients can access them, even when doctors believe they could help save lives; Canada’s largest charity dedicated to [...]
BlossomHill Therapeutics Expands Board of Directors with the Appointments of Sheila Gujrathi, M.D., and John Schmid
20/05/2026
Seasoned biopharmaceutical leaders bring significant clinical development, financial and strategic expertise to support BlossomHill's next phase of growth SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- BlossomHill [...]
Repligen Announces Publication of the Company’s 2025 Corporate Sustainability Report
20/05/2026
WALTHAM, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2025 Corporate [...]
New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
20/05/2026
Compared to patients adherent to monthly injectable buprenorphine, patients on other MOUD (adherent and non-adherent) were 3.5 to 8.1x more likely to return to opioid use. In a separate study, patients receiving monthly [...]
Aeroflow Urology Donates to National Diaper Bank Network and United Way to Improve National Health Equity
20/05/2026
Gifts to both organizations reflect Aeroflow Urology’s continuous commitment to community partnerships that directly support underserved families ASHEVILLE, N.C., May 20, 2026 (GLOBE NEWSWIRE) -- Aeroflow Urology , a [...]
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
20/05/2026
IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will [...]
Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk
20/05/2026
Secondary analysis from the Phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 trials examines improvements in lipid profiles for Lp(a), LDL-C and ApoB with Rezdiffra ® (resmetirom) Analysis of two-year data in patients with [...]
NetraMark to Present at the American Society of Clinical Psychopharmacology Annual Meeting
20/05/2026
Company to participate in plenary panel on artificial intelligence in psychiatry and present two scientific posters highlighting explainable AI applications in precision psychiatry TORONTO, May 20, 2026 (GLOBE NEWSWIRE [...]
Alzheimer’s Research Sites Honor National Clinical Trials Day
20/05/2026
Free Memory Screenings Offered to Promote Importance of Brain Health WASHINGTON, May 20, 2026 (GLOBE NEWSWIRE) -- Alzheimer’s research sites across the country are honoring National Clinical Trials Day by offering free [...]
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval
20/05/2026
- 72-week trial will enroll approximately 90 participants; first site now open for enrollment - - Primary endpoint is rise from floor (RFF) velocity with multiple secondary endpoints to assess muscle and pulmonary [...]
Codexis highlights stereochemistry advances for scalable RNA manufacturing at TIDES USA
20/05/2026
REDWOOD CITY, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Codexis, a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, shared new advances in RNA [...]
BioStem Technologies Announces Notice of Allowance for Four U.S. Design Patent Applications Covering Fenestrated Human Placental Allografts and One European Patent
20/05/2026
BioStem Technologies Expands Global Placental Allograft Patent Portfolio Pompano Beach, FL, May 20, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies®, a leading regenerative medicine company focused on developing and [...]
Emergent BioSolutions to Participate in Upcoming Investor Conferences
20/05/2026
GAITHERSBURG, Md., May 20, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following investor conferences: [...]
JenaValve Appoints Tonya Porter as Vice President of Regulatory Affairs
20/05/2026
IRVINE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the Trilogy® Transcatheter Heart Valve (THV) System, today announced the appointment of Tonya Porter as Vice [...]
Kraig Biocraft Laboratories Highlights Technical Breakthrough of Its Immortalized Silk Gland Cell Platform
20/05/2026
ANN ARBOR, Mich., May 20, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced additional [...]
Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants
20/05/2026
MALVERN, Pa., May 20, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]

Pages